PolyPeptide Group AG (SWX: PPGN)

PolyPeptide Group AG Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	82.44	82.5	145.47	144.24	78.36	71.01
Depreciation & Amortization	0.1	0.13	0.13	0.14	0.14	0.13
Operating Cash Flow	42.01	81.17	4.89	33.35	45.63	36.02
Operating Cash Flow Growth	-24.32%	1561.56%	-85.35%	-26.93%	26.68%	56.10%
Investing Cash Flow	-52.67	-10.19	133.68	50.22	45.83	28.54
Long-Term Debt Issued	-	86.4	-	119.82	41.25	70
Long-Term Debt Repaid	-	-100	-34	-156	-80.1	-155
Net Debt Issued (Repaid)	67.7	-13.6	-34	-36.18	-38.85	-85
Issuance of Common Stock	-	-	-	-	11.96	-
Repurchase of Common Stock	-	-0.63	-36.15	-1.65	-1.3	-54.88
Common Dividends Paid	-50.7	-92.18	-47.39	-47.5	-46.96	-41.32
Net Cash Flow	6.34	-35.43	21.03	-1.77	16.32	-116.63
Free Cash Flow	42.01	81.17	4.89	33.35	45.63	36.02
Free Cash Flow Growth	-24.32%	1561.56%	-85.35%	-26.93%	26.68%	56.10%
Free Cash Flow Margin	44.76%	47.18%	2.10%	17.98%	38.89%	37.91%
Free Cash Flow Per Share	4.56	8.81	0.53	3.51	4.85	3.79
Cash Interest Paid	6.7	7.02	6.13	7.89	9	11.64
Cash Income Tax Paid	5.48	19.56	43.53	32.25	9.33	16.94
Levered Free Cash Flow	36.73	89.54	94.73	88.03	80.62	46.87
Unlevered Free Cash Flow	40.91	93.4	98.54	93	86.2	53.07
Change in Net Working Capital	4.75	-35.06	22.82	9.82	-26.15	-6.77

Source: S&P Capital IQ. Standard template. Financial Sources.